Cardiovascular disease is an increasing risk of morbidity and mortality in cancer patients, related to an growing number of aging survivors with pre-existing cardiovascular disease and the use of traditional and novel cancer therapies with cardiotoxic effects. While many cardiac complications are chronic processes that develop over time, there are many acute processes that may arise in hospitalized patients. It is important for hospitalists and critical care physicians to be familiar with the recognition and management of these conditions in this unique population. This article reviews the presentation and management of common cardiac urgencies in critically ill cancer patients including acute decompensated heart failure, acute coronary syndromes, arrhythmias, hypertensive crises, pulmonary embolism, pericardial tamponade and myocarditis.
LyonARYousafNBattistiNMLMoslehiJLarkinJ. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458.
2.
AlviRMFrigaultMJFradleyMG, et al.Cardiovascular events among adults treated with chimeric antigen receptor t-cells(car-t). J Am Coll Cardiol. 2019;74(25):3099-3108.
3.
BallSGhoshRKWongsaengsakS, et al.Cardiovascular toxicities of immune checkpoint inhibitors. J Am Coll Cardiol. 2019;74(13):1714-1727.
BolandTALeeVHBleckTP.Stress-induced cardiomyopathy. Crit Care Med. 2015;43(3):686-693.
6.
ChampionSBelcourDVandrouxD, et al.Stress (Tako-tsubo) cardiomyopathy in critically-ill patients. Eur Heart J: Acute Cardiovasc Care. 2015;4(2):189-196.
7.
DesaiANoorAJoshiSKimAS. Takotsubo cardiomyopathy in cancer patients. Cardio-Oncol. 2019;5(1):7.
8.
ZaghlolRDeyAKBaracA. Takotsubo and cancer. Eur Heart J. 2020;41(48):4547-4549.
9.
LyonARLópez-FernándezTCouchLS, et al.2022 Esc guidelines on cardio-oncology developed in collaboration with the European hematology association (Eha), the European society for therapeutic radiology and oncology (Estro) and the international cardio-oncology society(Ic-os). Eur Heart J. 2022;43(41):4229-4361.
10.
DesaiRDesaiAAbbasSA, et al.National prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal/intrathoracic cancer and radiation therapy. Int J Cardiol. 2020;309:14-18.
11.
JamalFAKhaledSK. The cardiovascular complications of chimeric antigen receptor t cell therapy. Curr Hematol Malig Rep. 2020;15(2):130-132.
12.
HeidenreichPABozkurtBAguilarD, et al.2022 Aha/acc/hfsa guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
13.
OuwerkerkWTrompJClelandJGF, et al.Association of time-to-intravenous furosemide with mortality in acute heart failure: Data from REPORT-HF. Eur J Heart Fail. 2023;25(1):43-51.
14.
FelkerGMEllisonDHMullensWCoxZLTestaniJM. Diuretic therapy for patients with heart failure. J Am Coll Cardiol. 2020;75(10):1178-1195.
15.
WanSHStevensSRBorlaugBA, et al.Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: Results from the rose ahf trial(Renal optimization strategies evaluation in acute heart failure). Circ Heart Fail. 2016;9(8):e002593. doi:https://doi.org/10.1161/CIRCHEARTFAILURE.115.002593.
16.
AhmadTJacksonKRaoVS, et al.Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137(19):2016-2028.
17.
MebazaaADavisonBChioncelO, et al.Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (Strong-hf): A multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-1952.
18.
De BackerDBistonPDevriendtJ, et al.Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
19.
BloomJEChanWKayeDMStubD. State of shock: Contemporary vasopressor and inotrope use in cardiogenic shock. JAHA. 2023;12(15):e029787.
20.
BalthazarTVandenbrieleCVerbruggeFH, et al.Managing patients with short-term mechanical circulatory support. J Am Coll Cardiol. 2021;77(9):1243-1256.
21.
DhruvaSSRossJSMortazaviBJ, et al.Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734-745.
22.
KaramiMden UilCAOuweneelDMScholteNTBEngstromAESimao HenriquesJP. High-output mechanical circulatory support devices for cardiogenic shock after myocardial infarction: ECMO versus impella CP/5.0. ESC. Eur Heart J ACute Cardiovasc Care. 2020;9(2):164-172.
23.
GuhaADeyAKJneidHAddisonD. Acute coronary syndromes in cancer patients. Eur Heart J. 2019;40(19):1487-1490.
24.
SturgeonKMDengLBluethmannSM, et al.A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897.
25.
Al-HawwasMTsitlakidouDGuptaNIliescuCCilingirogluMMarmagkiolisK. Acute coronary syndrome management in cancer patients. Curr Oncol Rep. 2018;20(10):78.
26.
ThygesenKAlpertJSJaffeAS, et al.Fourth universal definition of myocardial infarction. Circulation. 2018;138(20):e618-e651.
27.
SarkissMGYusufSWWarnekeCL, et al.Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109(3):621-627.
28.
McCarthyCPStegGBhattDL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum. Eur Heart J. 2017;38(47):3488-3492.
29.
KofoedKFKelbækHHansenPR, et al.Early versus standard care invasive examination and treatment of patients with non-st-segment elevation acute coronary syndrome: Verdict randomized controlled trial. Circulation. 2018;138(24):2741-2750.
30.
MehtaSRGrangerCBBodenWE, et al.Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-2175.
31.
ChapmanARShahASVLeeKK, et al.Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation. 2018;137(12):1236-1245.
32.
BoschNACiminiJWalkeyAJ. Atrial fibrillation in the icu. Chest. 2018;154(6):1424-1434.
33.
ArtucioHPereiraM. Cardiac arrhythmias in critically ill patients: Epidemiologic study. Crit Care Med. 1990;18(12):1383-1388.
34.
JakobsenCBLambertsMCarlsonN, et al.Incidence of atrial fibrillation in different major cancer subtypes: A nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105.
35.
O’NealWTLakoskiSGQureshiW, et al.Relation between cancer and atrial fibrillation(from the reasons for geographic and racial differences in stroke study). Am J Cardiol. 2015;115(8):1090-1094.
36.
JoglarJAChungMKArmbrusterAL, et al.Acc/aha/accp/hrs guideline for the diagnosis and management of atrial fibrillation: a report of the american college of cardiology/american heart association joint committee onclinical practice guidelines. Circulation. 2024;149(1):E1-E156.
37.
LipGYHFrisonLHalperinJLLaneDA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile inr, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
38.
FradleyMGBeckieTMBrownSA, et al.Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e41-e55.
39.
D’SouzaMCarlsonNFosbølE, et al.CHA2DS2-VASc Score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25(6):651-658.
PastoriDMarangABissonA, et al.Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer. 2021;127(12):2122-2129.
42.
UllahWDiMeglioMFrischDR, et al.Outcomes and discriminatory accuracy of the cha2ds2vasc score in atrial fibrillation and cancer. JACC: Adv. 2023;2(8):100609.
43.
KearonCAklEAOrnelasJ, et al.Antithrombotic therapy for vte disease. Chest. 2016;149(2):315-352.
44.
MosarlaRCVaduganathanMQamarAMoslehiJPiazzaGGiuglianoRP. Anticoagulation strategies in patients with cancer. J Am Coll Cardiol. 2019;73(11):1336-1349.
45.
ShahSNorbyFLDattaYH, et al.Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-209.
46.
SenaratneJMSandhuRBarnettCFGrunauBWongGCvan DiepenS. Approach to ventricular arrhythmias in the intensive care unit. J Intensive Care Med. 2021;36(7):731-748.
47.
AnnaneDSébilleVDubocD, et al.Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 2008;178(1):20-25.
48.
RautaharjuPMSurawiczBGettesLS. Aha/accf/hrs recommendations for the standardization and interpretation of the electrocardiogram: part iv: the st segment, t and u waves, and the qt interval: a scientific statement from the American Heart Association electrocardiography and arrhythmias committee, council on clinical cardiology; the American College of Cardiology foundation; and the heart rhythm society: endorsed by the international society for computerized electrocardiology. Circulation. 2009;53(11):982-991.
49.
Porta-SánchezAGilbertCSpearsD, et al.Incidence, diagnosis, and management of qt prolongation induced by cancer therapies: A systematic review. JAHA. 2017;6(12):e007724.
50.
FernandesFMSilvaEPMartinsRROliveiraAG. QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. Erdoes G, ed. PLoS ONE. 2018;13(6):e0199028.
51.
FarzaneganBHosseinpoorZBaniasadiSSeyyediSRRajabiM. An observational study of qtc prolongation in critically ill patients: Identification of incidence and predictors. Indian J Crit Care Med. 2020;24(4):270-275.
52.
DrewBJAckermanMJFunkM, et al.Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology foundation. Circulation. 2010;121(8):1047-1060.
53.
KusumotoFMSchoenfeldMHBarrettC, et al.2018 acc/aha/hrs guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;74(7):932-987.
54.
WheltonPKCareyRMAronowWS, et al.2017 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e136-e139.
55.
CohenJBBrownNJBrownSA, et al.Cancer therapy–related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80(3):e46-e57.
56.
CampbellPBakerWLBendelSDWhiteWB. Intravenous hydralazine for blood pressure management in the hospitalized patient: Its use is often unjustified. J Am Soc Hypertens. 2011;5(6):473-477.
57.
FrancisCW. Prevention of venous thromboembolism in hospitalized patients with cancer. JCO. 2009;27(29):4874-4880.
58.
LevitanNDowlatiARemickSC, et al.Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291.
59.
XiongW. Current status of treatment of cancer-associated venous thromboembolism. Thrombosis J. 2021;19(1):21.
60.
GiriJSistaAKWeinbergI, et al.Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. Circulation. 2019;140(20):e774-e801.
61.
AujeskyDRoyPMVerschurenF, et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: An international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-48.
62.
PriceLCWortSJFinneySJMarinoPSBrettSJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: Current and emerging options for management: A systematic literature review. Crit Care. 2010;14(5):R169.
63.
KonstamMAKiernanMSBernsteinD, et al.Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-e622.
64.
Rivera-LebronBMcDanielMAhrarK, et al.Diagnosis, treatment and follow up of acute pulmonary embolism: Consensus practice from the pert consortium. Clin Appl Thromb Hemost. 2019;25:1076029619853037.
65.
FiumaraKKucherNFanikosJGoldhaberSZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006;97(1):127-129.
66.
AyCPoschF.Management of pulmonary embolism in patients with cancer. In: The ESC Textbook of Cardiovascular Medicine. Oxford; 2018:2790-2794.
67.
DudzinskiDMHorowitzJM. Start-up, organization and performance of a multidisciplinary pulmonary embolism response team for the diagnosis and treatment of acute pulmonary embolism. Revista Española de Cardiología (English Edition). 2017;70(1):9-13.
68.
KangDKThiloCSchoepfUJ, et al.Ct signs of right ventricular dysfunction. JACC: Cardiovasc Imag. 2011;4(8):841-849.
69.
CasazzaFBongarzoniACapoziAAgostoniO. Regional right ventricular dysfunction in acute pulmonary embolism and right ventricular infarction. Eur J Echocardiogr. 2005;6(1):11-14.
70.
RafieNFoleyDARipollJG, et al.Mcconnell’s sign is not always pulmonary embolism. JACC: Case Rep. 2022;4(13):802-807.
71.
PiazzaGGoldhaberSZ. Management of submassive pulmonary embolism. Circulation. 2010;122(11):1124-1129.
72.
BikdeliBLoboJLJiménezD, et al.Early use of echocardiography in patients with acute pulmonary embolism: Findings from the riete registry. JAHA. 2018;7(17):e009042.
73.
KelkarAHRajasekharA. Inferior vena cava filters: A framework for evidence-based use. Hematology. 2020;2020(1):619-628.
74.
ZuinMRigatelliGZonzinPRonconL. Inferior vena cava filters in hemodynamically unstable patients with acute pulmonary embolism: How often are they used? Data from multicenter prospective registries on acute pulmonary embolism. Cardiovasc Intervent Radiol. 2019;42(8):1073-1079.
75.
MaischBRisticAPankuweitS. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53(2):157-163.
76.
GhoshAKCrakeTManistyCWestwoodM. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018;20(7):60.
77.
SpodickDH. Acute cardiac tamponade. N Engl J Med. 2003;349(7):684-690.
78.
BeckCS. Two cardiac compression triads. JAMA. 1935;104(9):714.
79.
ImazioMAdlerY. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186-1197.
80.
RafiqueAMPatelNBinerS, et al.Frequency of recurrence of pericardial tamponade in patients with extended versus nonextended pericardial catheter drainage. Am J Cardiol. 2011;108(12):1820-1825.
81.
ThiagarajanPAfshar-KharghanV. Platelet transfusion therapy. Hematol Oncol Clin North Am. 2013;27(3):629-643.
82.
WilsonNRLeeMTGillCD, et al.Prognostic factors and overall survival after pericardiocentesis in patients with cancer and thrombocytopenia. Front Cardiovasc Med. 2021;8:638943.
83.
HaddadEIliescuDYusufC, et al.Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol. 2015;66(10):1119-1128.
84.
BassoC. Myocarditis. Longo DL, ed. N Engl J Med. 2022;387(16):1488-1500.
85.
BonacaMPOlenchockBASalemJE, et al.Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80-91.
86.
ThunyFBonacaMPCautelaJ. What is the evidence of the diagnostic criteria and screening of immune checkpoint inhibitor–induced myocarditis?JACC: CardioOncol. 2022;4(5):624-628.
FerreiraVMSchulz-MengerJHolmvangG, et al.Cardiovascular magnetic resonance in nonischemic myocardial inflammation. J Am Coll Cardiol. 2018;72(24):3158-3176.
89.
CaforioALPPankuweitSArbustiniE, et al.Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636-2648, 2648a-2648d.
90.
SchneiderBJNaidooJSantomassoBD, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update. J Clin Oncol. 2021;39(36):4073-4126.
91.
ZhangJGajjalaSAgrawalP, et al.Fully automated echocardiogram interpretation in clinical practice: Feasibility and diagnostic accuracy. Circulation. 2018;138(16):1623-1635.
92.
BrahmerJRAbu-SbeihHAsciertoPA, et al.Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.
93.
SalemJEAllenbachYVozyA, et al.Abatacept For severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377-2379.
94.
NguyenLSBretagneMArrondeauJ, et al.Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted Abatacept and ruxolitinib: Proof of concept. J Immunother Cancer. 2022;10(4):e004699.
95.
LabovitzAJNobleVEBierigM, et al.Focused cardiac ultrasound in the emergent setting: A consensus statement of the American society of echocardiography and American college of emergency physicians. J Am Soc Echocardiogr. 2010;23(12):1225-1230.
96.
SabiaPAbbottRDAfrooktehAKellerMWTouchstoneDAKaulS. Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms. Circulation. 1991;84(4):1615-1624.
97.
KircherBJHimelmanRBSchillerNB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol. 1990;66(4):493-496.
98.
RibeiroALindmarkerPJuhlin-DannfeltAJohnssonHJorfeldtL. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134(3):479-487.
99.
KasperWKonstantinidesSGeibelA, et al.Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol. 1997;30(5):1165-1171.
100.
MandaviaDPHoffnerRJMahaneyKHendersonSO. Bedside echocardiography by emergency physicians. Ann Emerg Med. 2001;38(4):377-382.
